Table 2.
Overall survival in months of patients receiving platinum-based chemotherapy (1) or not (0), with respect to their eIF3a expression status.
| eIF3a expression | ||
|---|---|---|
| Low | High | |
| Platinum-based chemotherapy |
Average overall survival (months) | |
|
| ||
| 1 | 67.2 | 27.9 |
| 0 | 53.3 | 35.7 |